Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine Combined with Homoharringtonine vs Azacitidine in MDS and AML-MRC
NCT03978364Phase 3Unknown
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of homoharringtonine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Disease free survival at 3 years. Status: unknown.
02
Drugs
homoharringtonine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03978364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978364.